Dopavision is a digital-health startup based in Berlin. Our goal is to disrupt vision care with digital solutions. After our Series A last year backed by Novartis and other investors, we are focusing on myopia, or shortsightedness: 200 million children globally are suffering from progressive myopia and the incidence is rising dramatically across the globe.
We are developing a digital treatment to slow myopia progression in children in the form of a smartphone app, to be used with a virtual or augmented reality device. We are conducting a European-wide clinical study supported by large pharmaceutical companies while continuing to improve our product.